Benitec Biopharma Inc. BNTC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.54M | 7.28M | 7.54M | 6.43M | 6.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.43M | 13.58M | 13.38M | 9.80M | 9.83M |
| Operating Income | -14.43M | -13.58M | -13.38M | -9.80M | -9.83M |
| Income Before Tax | -12.81M | -11.94M | -11.84M | -8.97M | -8.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.81M | -11.94M | -11.84M | -8.97M | -8.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.81M | -11.94M | -11.84M | -8.97M | -8.81M |
| EBIT | -14.43M | -13.58M | -13.38M | -9.80M | -9.83M |
| EBITDA | -14.41M | -13.57M | -13.36M | -9.79M | -9.82M |
| EPS Basic | -0.26 | -0.24 | -0.26 | -0.22 | -0.21 |
| Normalized Basic EPS | -0.16 | -0.15 | -0.16 | -0.13 | -0.13 |
| EPS Diluted | -0.26 | -0.24 | -0.26 | -0.22 | -0.21 |
| Normalized Diluted EPS | -0.16 | -0.15 | -0.16 | -0.13 | -0.13 |
| Average Basic Shares Outstanding | 49.44M | 49.39M | 45.97M | 41.52M | 41.16M |
| Average Diluted Shares Outstanding | 49.44M | 49.39M | 45.97M | 41.52M | 41.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |